Significant comment from KZA boss Dr James Garner, in a 27 Dec 2017 ASX release may have been missed by some investors here. In fact, I have only just noticed this wording, in once again reading that announcement.
KZA has been conducting a Phase 1 Clinical OPEN label trial on Cantrixil for the last 12 months. In that release, Dr Garner states.......
"we are delighted to facilitate the future success of NOX........"
What do you think? How can such a comment be made - unusually bold in the context of both companies still only in Phase 1 trials......unless as I think, some strong data has come in the last 12 months.
Dr Kelly of a view this drug can become the mainstay of abdominal cancer treatment. So little snippets like this are very significant.
NOX Price at posting:
$1.12 Sentiment: None Disclosure: Not Held
(20min delay)